Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
or

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)
817.80 x 1,000 824.00 x 100
Post-market by (Cboe BZX)
818.02 -21.94 (-2.61%) 04/21/25 [NYSE]
817.80 x 1,000 824.00 x 100
Post-market 818.50 +0.48 (+0.06%) 19:54 ET
Quote Overview for Mon, Apr 21st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
807.00
Day High
843.91
Open 841.51
Previous Close 839.96 839.96
Volume 3,326,600 3,326,600
Avg Vol 3,908,460 3,908,460
Stochastic %K 85.99% 85.99%
Weighted Alpha +5.33 +5.33
5-Day Change +85.61 (+11.69%) +85.61 (+11.69%)
52-Week Range 677.09 - 972.53 677.09 - 972.53
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 796,424,896
  • Shares Outstanding, K 948,170
  • Annual Sales, $ 45,043 M
  • Annual Income, $ 10,590 M
  • EBIT $ 12,899 M
  • EBITDA $ 14,666 M
  • 60-Month Beta 0.51
  • Price/Sales 15.47
  • Price/Cash Flow 51.63
  • Price/Book 48.88

Options Overview Details

View History
  • Implied Volatility 42.49% ( +0.40%)
  • Historical Volatility 55.57%
  • IV Percentile 92%
  • IV Rank 47.61%
  • IV High 64.53% on 04/07/25
  • IV Low 22.46% on 06/28/24
  • Put/Call Vol Ratio 1.32
  • Today's Volume 48,767
  • Volume Avg (30-Day) 36,972
  • Put/Call OI Ratio 1.04
  • Today's Open Interest 259,705
  • Open Int (30-Day) 262,447

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 24 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 4.44
  • Number of Estimates 9
  • High Estimate 5.13
  • Low Estimate 3.73
  • Prior Year 2.58
  • Growth Rate Est. (year over year) +72.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
677.09 +20.81%
on 04/07/25
Period Open: 837.57
874.92 -6.50%
on 03/25/25
-19.55 (-2.33%)
since 03/21/25
3-Month
677.09 +20.81%
on 04/07/25
Period Open: 742.35
935.63 -12.57%
on 03/03/25
+75.67 (+10.19%)
since 01/21/25
52-Week
677.09 +20.81%
on 04/07/25
Period Open: 726.31
972.53 -15.89%
on 08/22/24
+91.71 (+12.63%)
since 04/19/24

Most Recent Stories

More News
Down 61%, Is Novo Nordisk Stock Worth Buying on the Dip?

Novo Nordisk (NYSE: NVO) stock hit an all-time high of $148.15 in June 2024, marking a remarkable fivefold surge since 2019. Yet the stock has since plummeted 61% from its peak value.

NVO : 58.33 (+0.43%)
LLY : 818.02 (-2.61%)
Stocks Set to Open Sharply Lower After Trump’s Push Against Powell, U.S. Economic Data and Tech Earnings in Focus

June S&P 500 E-Mini futures (ESM25) are down -1.09%, and June Nasdaq 100 E-Mini futures (NQM25) are down -1.23% this morning, pointing to a sharply lower open on Wall Street as U.S. President Donald Trump’s...

GOOGL : 147.67 (-2.31%)
AVGO : 166.21 (-2.80%)
VZ : 42.93 (-2.52%)
MRK : 77.85 (-0.19%)
TXN : 145.61 (-1.91%)
UNH : 425.33 (-6.34%)
ESM25 : 5,205.25 (+0.40%)
TSLA : 227.50 (-5.75%)
T : 26.33 (-3.02%)
IBM : 236.22 (-1.08%)
LLY : 818.02 (-2.61%)
NQM25 : 17,990.25 (+0.38%)
Did Eli Lilly Just Say Checkmate to Novo Nordisk?

Novo Nordisk (NYSE: NVO) has seen revenue soar in recent years thanks to two drugs that have helped people around the world lose weight. The molecule is semaglutide, and it's sold under the name Ozempic...

VKTX : 23.72 (-0.92%)
NVO : 58.33 (+0.43%)
LLY : 818.02 (-2.61%)
GS : 501.36 (-1.60%)
Prediction: Eli Lilly's Newest GLP-1 Drug Will Be a Game-Changer for the Stock

Drugmaker Eli Lilly (NYSE: LLY) hasn't been exempt from the recent market pullback, but its stock shot higher following the announcement that its newest GLP-1 drug had successfully completed the first...

LLY : 818.02 (-2.61%)
Is Eli Lilly Stock a Buy Right Now?

The pharmaceutical sector could be the next industry to face sweeping tariffs from the Trump administration.

LLY : 818.02 (-2.61%)
Eli Lilly's Experimental Weight Loss Pill Succeeded in Its First Pivotal Trial. Is It Time to Buy?

More than 2 out of 5 American adults are obese, according to the Centers for Disease Control. With this figure in mind, it's no wonder Wall Street investment banks are telling anyone who will listen that...

NVO : 58.33 (+0.43%)
MS : 106.30 (-2.64%)
LLY : 818.02 (-2.61%)
Goldman Sachs Just Upgraded This Blue-Chip Stock. Should You Buy It Now?

With a strong pipeline, this pharmaceutical powerhouse is positioning itself as a dominant force in the future of medicine.

$SPX : 5,158.20 (-2.36%)
LLY : 818.02 (-2.61%)
Where Will Eli Lilly Be in 5 Years?

What a difference five years can make. Just look at Eli Lilly (NYSE: LLY) . In April 2020, the drugmaker stood in the shadows to some extent with companies including Johnson & Johnson, Pfizer , and Merck...

NVO : 58.33 (+0.43%)
MRK : 77.85 (-0.19%)
JNJ : 156.92 (-0.35%)
LLY : 818.02 (-2.61%)
PFE : 22.04 (-0.45%)
Stocks Settle Mixed as Energy Producers Rally and Health Insurers Fall

The S&P 500 Index ($SPX ) (SPY ) Thursday closed up +0.13%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -1.33%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed unchanged. June E-mini S&P...

MPC : 126.72 (-0.78%)
CVS : 65.17 (-3.15%)
AVGO : 166.21 (-2.80%)
GPN : 67.47 (-2.86%)
TTD : 47.56 (-5.37%)
HBAN : 13.47 (-1.46%)
SNA : 292.36 (-4.28%)
SLB : 34.62 (-1.40%)
QXO : 12.72 (-3.27%)
$IUXX : 17,808.30 (-2.46%)
UNH : 425.33 (-6.34%)
ELV : 406.69 (-4.20%)
Why Eli Lilly Stock Is Soaring Today, While Novo Nordisk and Viking Therapeutics Slide

Eli Lilly has a plan to dominate the GLP-1 weight loss drug market -- and it's succeeding.

VKTX : 23.72 (-0.92%)
NVO : 58.33 (+0.43%)
HIMS : 25.84 (-5.10%)
LLY : 818.02 (-2.61%)
PFE : 22.04 (-0.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure...

See More

Key Turning Points

3rd Resistance Point 875.86
2nd Resistance Point 859.89
1st Resistance Point 838.95
Last Price 818.02
1st Support Level 802.04
2nd Support Level 786.07
3rd Support Level 765.13

See More

52-Week High 972.53
Fibonacci 61.8% 859.67
Fibonacci 50% 824.81
Last Price 818.02
Fibonacci 38.2% 789.95
52-Week Low 677.09

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro